Aeris Therapeutics Report issue

For profit Phase 2
Founded: Woburn MA United States (2000)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
2007
NCT00517998
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

aluminum hydroxide (Gaviscon) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Emphysema (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Pulmonary Emphysema (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1